Lyme disease chemoprophylaxis prescribing before and after pharmacist prescriptive authority in Nova Scotia
- PMID: 39563711
- PMCID: PMC11571129
- DOI: 10.1177/17151635241290519
Lyme disease chemoprophylaxis prescribing before and after pharmacist prescriptive authority in Nova Scotia
Abstract
Background: Lyme disease is a bacterial infection transmitted to humans through bites from infected Ixodes species of ticks. Prophylaxis with a single dose of oral doxycycline following a bite from an infected tick reduces the risk of developing Lyme disease. Pharmacists in Nova Scotia (NS) were among the first in Canada to prescribe for this indication. The primary objective of this study is to describe experiences with pharmacist prescribing of prophylaxis after tick bites in NS.
Methods: A retrospective cohort study was performed using health administrative data 16 months before and after pharmacists were authorized to prescribe Lyme disease chemoprophylaxis (August 1, 2021). All dispensations of a single dose of oral doxycycline from a community pharmacy in NS were included. Data collected included prescriber type, date, and county of dispensation. Comparisons of dispensations were completed before and after pharmacists gained prescriptive authority and relative to other prescribers. Dispensations were described descriptively.
Results: Over the study period, 12,549 single-dose doxycycline prescriptions were dispensed in NS: 3900 prescriptions were dispensed before pharmacist prescribing authorization for this indication occurred and 8649 were dispensed after. Pharmacists prescribed 61.3% of all single-dose doxycycline prescriptions following implementation of prescribing authority.
Discussion: An increase in single-dose doxycycline prescriptions was observed in NS. Pharmacists have become the primary prescribers for Lyme disease chemoprophylaxis in the province.
Conclusion: Patients were willing to be assessed for chemoprophylaxis after tick exposure by pharmacists, and pharmacist prescribing for this indication suggests increased access to post-tick exposure care.
© The Author(s) 2024.
Conflict of interest statement
Since completing this project, Dr. Emily Black has received funding from Shoppers Drug Mart to explore pharmacist prescribing for infectious diseases and from Pfizer Canada for unrelated work on immunizations. Other authors have no financial or personal relationships with commercial entities to disclose.
Figures
Similar articles
-
Pharmacist initiation of postexposure doxycycline for Lyme disease prophylaxis.J Am Pharm Assoc (2003). 2014 Jan-Feb;54(1):69-73. doi: 10.1331/JAPhA.2014.13106. J Am Pharm Assoc (2003). 2014. PMID: 24407743
-
Implementing a pharmacist-run Lyme disease postexposure prophylaxis clinic augmented by academic detailing within the Veterans Health Administration.J Am Pharm Assoc (2003). 2020 Sep-Oct;60(5):e70-e75. doi: 10.1016/j.japh.2020.01.002. Epub 2020 Feb 13. J Am Pharm Assoc (2003). 2020. PMID: 32061509
-
Uptake of community pharmacist prescribing over a three-year period.Explor Res Clin Soc Pharm. 2023 Jan 7;9:100221. doi: 10.1016/j.rcsop.2023.100221. eCollection 2023 Mar. Explor Res Clin Soc Pharm. 2023. PMID: 36703714 Free PMC article.
-
Prevention of Lyme borreliosis.Wien Klin Wochenschr. 2005 Jun;117(11-12):385-91. doi: 10.1007/s00508-005-0362-7. Wien Klin Wochenschr. 2005. PMID: 16053192 Review.
-
Antibiotic prophylaxis for prevention against Lyme disease following tick bite: an updated systematic review and meta-analysis.BMC Infect Dis. 2021 Nov 8;21(1):1141. doi: 10.1186/s12879-021-06837-7. BMC Infect Dis. 2021. PMID: 34749665 Free PMC article.
References
-
- Lantos PM, Rumbaugh J, Bockenstedt LK, et al.. Clinical practice guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 guidelines for the prevention, diagnosis and treatment of Lyme disease. Clin Infect Dis 2021;72(1):1-48. - PubMed
-
- Lyme disease. IPAC Canada. Available: https://ipac-canada.org/lyme-disease (accessed Jun. 30, 2023).
-
- Communicable disease prevention and control: Lyme disease. Government of Nova Scotia. 2021. Available: https://novascotia.ca/dhw/cdpc/lyme.asp (accessed Nov. 4, 2023).
-
- Lyme disease: prevention and treatment. Public Health Agency of Canada. 2022. Available: https://www.canada.ca/en/public-health/services/diseases/lyme-disease.html (accessed Jun. 3, 2023).
LinkOut - more resources
Full Text Sources
Miscellaneous